Catal­ent’s Covid-19 vac­cine man­u­fac­tur­ing site hit with Form 483 over for­eign ob­jects in vials and oth­er QC is­sues

An In­di­ana-based Catal­ent fa­cil­i­ty that pro­duces Covid-19 vac­cines is fac­ing scruti­ny from the FDA over an in­spec­tion last month.

Catal­ent’s plant in Bloom­ing­ton, IN, which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.